The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Official Title: Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Study ID: NCT00609804
Brief Summary: This is a randomized, open-label, multi-center, Phase II study of treatment of patients with advanced NSCLC who have progressed on erlotinib with the combination of sorafenib and erlotinib or sorafenib alone.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Florida Cancer Specialists, Fort Myers, Florida, United States
Northeast Georgia Medical Center, Gainesville, Georgia, United States
Wellstar Cancer Research, Marietta, Georgia, United States
Providence Medical Group, Terre Haute, Indiana, United States
Norton Cancer Institute, Louisville, Kentucky, United States
Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana, United States
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
National Capital Clinical Research Consortium, Bethesda, Maryland, United States
Jackson Oncology Associates, Jackson, Mississippi, United States
St. Louis Cancer Care, Chesterfield, Missouri, United States
Research Medical Center, Kansas City, Missouri, United States
Nebraska Methodist Cancer Center, Omaha, Nebraska, United States
Hematology-Oncology Associates of Northern NJ, Morristown, New Jersey, United States
Associates in Hematology Oncology, Chattanooga, Tennessee, United States
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Name: David Spigel, M.D.
Affiliation: SCRI Development Innovations, LLC
Role: STUDY_CHAIR